Nucleotide vector vaccine for immunization against hepatitis

Details Nucleotide vector vaccine for immunization against hepatitis Nucleotide vector vaccine for immunization against hepatitis

2003-08-20

2010-11-02

Falk, Anne-Marie (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S320100

Reexamination Certificate

active

07825097

ABSTRACT:
Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus.A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibres.

REFERENCES:
patent: 565203 (1896-08-01), Gluck et al.
patent: 4547367 (1985-10-01), Tabor et al.
patent: 4592742 (1986-06-01), Landau
patent: 4710463 (1987-12-01), Murray et al.
patent: 4803164 (1989-02-01), Hitzeman et al.
patent: 4839277 (1989-06-01), Sugahara et al.
patent: 4957869 (1990-09-01), Arnot et al.
patent: 5019386 (1991-05-01), Machida et al.
patent: 5256553 (1993-10-01), Overell et al.
patent: 5256767 (1993-10-01), Salk et al.
patent: 5565203 (1996-10-01), Glück et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5620896 (1997-04-01), Herrmann et al.
patent: 5643578 (1997-07-01), Robinson et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5714316 (1998-02-01), Weiner et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5780448 (1998-07-01), Davis
patent: 5786189 (1998-07-01), Locht et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5814617 (1998-09-01), Hoffman et al.
patent: 5817637 (1998-10-01), Weiner et al.
patent: 5830876 (1998-11-01), Weiner et al.
patent: 5830877 (1998-11-01), Carson et al.
patent: 5856462 (1999-01-01), Agrawal
patent: 5972346 (1999-10-01), Hauser et al.
patent: 5981274 (1999-11-01), Tyrrell et al.
patent: 5985847 (1999-11-01), Carson et al.
patent: 6635624 (2003-10-01), Davis et al.
patent: 2002/0142978 (2002-10-01), Raz et al.
patent: 2002/0192184 (2002-12-01), Carpentier
patent: 1 169 793 (1984-06-01), None
patent: 0 156 712 (1985-10-01), None
patent: 0 185 573 (1986-06-01), None
patent: WO 88/06185 (1988-08-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 92/06212 (1992-04-01), None
patent: WO 93/09236 (1993-05-01), None
patent: WO 93/15207 (1993-08-01), None
patent: WO 93/17111 (1993-09-01), None
patent: WO 95/05853 (1995-03-01), None
patent: WO 93/11307 (1995-04-01), None
patent: WO-9728259 (1997-08-01), None
patent: WO-2005004910 (2005-01-01), None
patent: WO-2005039633 (2005-05-01), None
Babiuk et al. (2003) Induction of immune responses by DNA vaccines in large animals. Vaccine 21: 649-658.
Ertl et al. (1996) Genetic immunization. Viral Immunology 9(1): 1-9.
Davis et al., Chapter 18: DNA-based immunization. in Molecular and Cell Biology of Human Gene Therapeutics. George Dickson, ed., 1995: p. 368-87. (ISBN: 0 412 62550 4).
Hahm et al., Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B. Int J Immunopharmacol. Mar. 1994;16(3):217-25.
Liu et al., Immunization of non-human primates with DNA vaccines. Vaccine. Jun. 1997;15(8):909-12.
Michel et al., DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A. Jun. 6, 1995;92(12):5307-11.
Staats et al., Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol. Aug. 1994;6(4):572-83. Review.
Alpar et al., Potential of particulate carriers for the mucosal delivery of DNA vaccines. Biochem Soc Trans. May 1997;25(2):337S.
Branda et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol. May 25, 1993;45(10):2037-43.
Calarota et al., Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. May 2, 1998;351(9112):1320-5.
Chen et al., Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol. Jul. 1998;72(7):5757-61.
Daheshia et al., Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine. Jul. 1998;16(11-12):1103-10.
Davis et al., Plasmid DNA expression systems for the purpose of immunization. Curr Opin Biotechnol. Oct. 1997;8(5):635-46.
Etchart et al., Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol. Jul. 1997;78 ( Pt 7):1577-80.
Fields et al., Fields' Virology. 2001;1:1153.
Gallichan et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. Nov. 1995;13(16):1589-95.
Geissler et al., Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. Feb. 1, 1995;158(3):1231-7.
Gramzinski et al., Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med. Feb. 1998;4(2):109-18.
Halperin et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. Jun. 2003 2;21(19-20):2461-7.
Halperin et al., Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine. Jan. 9, 2006;24(1):20-6. Epub Sep. 12, 2005. Abstract Only.
Hedley et al., Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med. Mar. 1998;4(3):365-8.
Jones et al., Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. Jun. 1997;15(8):814-7.
Klinman et al., Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. Apr. 1998;8(2):181-4.
Leclerc et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. Aug. 1, 1997;179(2):97-106.
Lee et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. Immunology. Jul. 1998;94(3):285-9.
MacGregor et al., First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. Jul. 1998;178(1):92-100.
McCluskie et al., Novel strategies using DNA for the induction of mucosal immunity. Crit Rev Immunol. 1999;19(4):303-29.
McCluskie et al., Novel adjuvant systems. Curr Drug Targets Infect Disord. Nov. 2001;1(3):263-71.
McCuskie et al., Mucosal immunization with DNA vaccines. Microbes Infect. Jul. 1999;1(9):685-98.
McCluskie et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000;22(1-2):125-32.
McCluskie et al., Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med. May 1999;5(5):287-300.
Payette et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. Nov. 2001;1(3):241-7.
Roman et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. Aug. 1997;3(8):849-54.
Rubanyi, The future of human gene therapy. Mol Aspects Med. Jun. 2001;22(3):113-42.
Tacket et al., Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine. Jul. 16, 1999;17(22):2826-9.
Ugen et al., DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. Nov. 1998;16(19):1818-21.
Wang et al., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. Oct. 16, 1998;282(5388):476-80.
Weeratna et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. Aug. 1998;8(4):351-6.
Weeratna et al., CpG DNA induces stronger immune responses

Affiliated with

Also associated with

Rating

Nucleotide vector vaccine for immunization against hepatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleotide vector vaccine for immunization against hepatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleotide vector vaccine for immunization against hepatitis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4229542